Register Login
Register to leave comments
  • News bot April 7, 2026, 12:15 p.m.

    📋 CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) - Clinical Trial Update

    Filing Date: 2026-04-07

    Accepted: 2026-04-07 08:15:07

    Event Type: Clinical Trial Update

    Event Details:

    CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) Announces Clinical Trial Update CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: path, accepted
    • Diseases/Conditions: CRB-701
    • Collaboration: Norwood
      • targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
      • targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical cancer. Corbus also announced that Dr. Dominic Smethurst, MA, MRCP is stepping down from his role as Chief Medical Officer; his last day with the company will be June 30, 2026

    🔬 Clinical Development Pipeline (CORBUS PHARMACEUTICALS HOLDINGS, INC.):

    Product Type Development Stage Therapeutic Area Source
    CRB-701 DRUG Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    CRB-913 DRUG Phase PHASE1 Obese But Otherwise Healthy Participants ClinicalTrials.gov
    LB-102 DRUG Phase PHASE3 Schizophrenia ClinicalTrials.gov
    JBT-101 (lenabasum) DRUG Phase PHASE2 Cystic Fibrosis ClinicalTrials.gov
    Placebo oral capsule OTHER Phase PHASE3 Diffuse Cutaneous Systemic Sclerosis ClinicalTrials.gov
    Part B Open-Label Extension DRUG Phase PHASE2 Diffuse Cutaneous Systemic Sclerosis ClinicalTrials.gov
    JBT-101 DRUG Phase PHASE2 Diffuse Cutaneous Systemic Sclerosis ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Obese But Otherwise Healthy Participants ClinicalTrials.gov
    Lenabasum 5 mg DRUG Phase PHASE3 Diffuse Cutaneous Systemic Sclerosis ClinicalTrials.gov
    Lenabasum 20 mg DRUG Phase PHASE3 Diffuse Cutaneous Systemic Sclerosis ClinicalTrials.gov
    Anti-PD-1 DRUG Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    Anti-PD-1 monoclonal antibody DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    CRB-601 monoclonal antibody DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CORBUS PHARMACEUTICALS HOLDINGS, INC.
    • Ticker Symbol: CRBP

Search

News categories